Glutathione
Glutathione is a powerful anti-oxidant required for the detoxification of toxins and maintenance of cellular health. When administered intravenously in high doses, glutathione increases the uptake of cysteine (an amino acid) into cells which works to protect the body from toxicity through increasing liver function. For many Parkinson’s patients glutathione replenishment has proven to be an effective therapy for halting or even reversing disability.
Conditions Regularly Treated:
- Parkinson’s Disease
- Hepatitis
- Toxicity
- Neuropathy
- Peripheral Arterial Diseases (PAD)
- NASH
Sampling of Clinical Research
Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. European Journal of Cancer. Volume 44, Issue 11, July 2008, Pages 1507-1515.
Stefano Cascinu, Vincenzo Catalano, Luigi Cordella, Roberto Labianca, Paolo Giordani, Anna Maria Baldelli, Giordano D. Beretta, Emilio Ubiali, Giuseppina Catalano. Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial . Journal of Clinical Oncology. Volume 20, Issue 16, August, 2002, Pages 3478-3483.
S. Aebi, R. Assereto, B.H. Lauterburg. High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. European Journal of Clinical Investigation.Volume 21, Issue 1, March 20, 2008, Pages 103 – 110.
AEBI, S., ASSERETO, R. and LAUTERBURG, B.H. (1991), High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. European Journal of Clinical Investigation, 21: 103–110. doi: 10.1111/j.1365-2362.1991.tb01366.x.
Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM, Rosati G. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 1996 Oct;20(7):1159-70.
Dalhoff K, Ranek L, Mantoni M, Poulsen, HE. Glutathione treatment of hepatocellular carcinoma. Liver 1992;12:341-343.
Novi AM. Regression of aflatoxin B1-induced hepatocellular carcinomas by reduced glutathione. Science 1981;212:541-542.
Kidd PM. Glutathione: systemic protectant against oxidative and free radical damage. Altern Med Rev 1997;2:155-176.
DeMaria D, Falchi AM, Venturino P. Adjuvant radiotherapy of the pelvis with or without reduced glutathione: a randomized trial in patients operated on for endometrial cancer. Tumori 1992;78:374-376.
Meijer C, Mulder NH, de Vries EGE. The role of detoxifying systems in resistance of tumor cells to cisplatin and adriamycin. Cancer Treat Rev 1990;17:389-407.
Smyth JF, Bowman A, Parren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol 1997;8:569-573. Bogliun G, Marzorati L, Marzola M, et al. Neurotoxicity of cisplatin +/- reduced glutathione in the first-line treatment of advanced ovarian cancer. Int J Gynaecol Cancer 1996;6:415-419.
Cascinu S, Cordella L, Del Ferro E, et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 1995;13:26-32.
Di Re F, Bohm S, Oriana S, et al. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. Ann Oncol 1993;4:55-61.
Locatelli MC, D'Antonia A, Lablanca R, et al. A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity. Tumori 1993;79:37-39.
Meet With A Doctor
The easiest way to get started is to schedule a free 15 minute coordination meeting to discuss what lab tests will help meet your health goals and whether we can run these tests through your insurance provider.
